HBMN:SWX
HBM Healthcare Investments AG
223,50 CHF
0,00%
(0,00) 1d
12 de nov., 17:30:00 GMT+1 · CHF
search
Tots els símbols
| Símbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadístiques principals per a HBMN...
Obre
224,00 CHF
Alt
225,00 CHF
Baix
221,00 CHF
Capitalització borsària
1478,45 M
Volum mitjà
5,87 k
Volum
5,63 k
Dividend
4,03 %
Dividend trimestral
2,25 CHF
Data de l'exdividend
17 de juny 2026
Ràtio preu-benefici
4,20
Alt 52 setmanes
258,00 CHF
Baix 52 setmanes
195,40 CHF
BPA
53,19 CHF
Accions en circulació
6,62 M
Obre
224,00 CHF
Alt
225,00 CHF
Baix
221,00 CHF
Capitalització borsària
1478,45 M
Volum mitjà
5,87 k
Volum
5,63 k
Dividend
4,03 %
Dividend trimestral
2,25 CHF
Data de l'exdividend
17 de juny 2026
Ràtio preu-benefici
4,20
Alt 52 setmanes
258,00 CHF
Baix 52 setmanes
195,40 CHF
BPA
53,19 CHF
Accions en circulació
6,62 M
Notícies
De fonts web i partners de notícies
Comercio TV
·
fa 8 hores
¿Cómo cerraron el Nasdaq, S&P 500 y Dow Jones el día de la renuncia de Jensen Huang?
The Coin Republic
·
fa 1 dia
Las acciones de Berkshire Hathaway superan al S&P 500 por el mayor margen en 16 años
XTB.com
·
fa 1 dia
DAX vs. S&P 500: ¿Europa lidera la recuperación bursátil?
www.tmgm.com
·
fa 20 hores
S&P 500: el repunte tecnológico contrarresta la oleada de ventas tras el IPC – Deutsche Bank
Perfil
HBM Healthcare Investments is a publicly traded Swiss investment and venture capital firm focusing on emerging technologies in the global healthcare sector. Within healthcare their focus is predominantly in biotechnology, medical technology, diagnostics, therapeutics and digital health.
A 2022 article in Swiss daily Luzerner Zeitung profiled HBM and interviewed its CEO, and described the company’s investment strategy as focused on early-stage but post-seed round opportunities.
Founded in July 2001 as HBM Bioventures AG by former Roche Chief Financial Officer Henri B. Meier who was its first Chairperson of the Board. A Handelszeitung article from 2020 described Meier's goal when founding the company as to profit from the "thesis" that from the 2000s onwards "Big Pharma is doing less and less research and development itself and is instead acquiring promising biotech companies" In an analysis of how HBM was put together, Swiss magazine Finanz und Wirtschaft described how he was able to raise almost 500 million Swiss Francs for the company launch. HBM is based in Zug and managed by HBM Partners. HBM acquired rival Swiss VC International BM Biomedicine in 2005. Wikipedia
Sobre HBM Healthcare Investments AG
Conseller delegat-
Empleats-
Fundació12 de jul. 2001
Seu principalZug, Cantó de Zug, Suïssa
SectorFinancials
Sector-
Lloc webhbmhealthcare.com